Wei Shen Tan

Urologic oncology @Yale_Urology | Hon Assoc Prof @UCLDivofSurgery | Hunterian Prof @RCSnews | Previously @MDAndersonNews @UCLH @uclhrobotics @NorthLonUrol

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

People have been DM and asking me: with an HR of 0.68 for durvalumab + BCG in POTOMAC, why isn’t this for every high-risk NMIBC patient?

Here’s how hazard ratios work – and why they can mislead you if you stop there. 🧵 #ASCO26

@tompowles1 @WesKassouf @shilpaonc @DrFelixGuerrero

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Time to revisit something I’ve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction.

Yet some frameworks allow < 3cm TaHG tumors to be downgraded into “intermediate risk” alongside low-grade disease.

That classification has real consequences for patients:
• undertreatment
• less rigorous surveillance
• in some studies, these patients are even placed on observation as a supposedly appropriate “control arm.”

TaHG is high risk. 🧵 @BladderCancerUS @WorldBladderCan @IBCG_BladderCA

[Wei Shen Tan @drtanws]

@DrMotamedinia @ellenmcahill @Yale_Urology @SMSNA_ORG Congrars Ellen! What a crowd !

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

One of the most exciting talks at #AUA26 - @jteoh_hk from @CUHKMedicine delivering the John K. Lattimer Lecture - one of the most prestigious in urology.
Jeremy is not just a friend and a colleague. He is one of the most innovative urologists of his generation and a driving force in the @IBCG_BladderCA.
Today he is challenging the status quo on TURBT. 🧵

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Testosterone replacement therapy after surgery for #prostatecancer🚨

@JAMAInternalMed

⭐️SPIRIT trial

📊 RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men
⏱️ TRT started ≥2 yrs post-RP w/ undetectable PSA
💉 12 wks testosterone vs placebo
✅ ↑ sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak
🛡️ ZERO biochemical recurrences

⚠️ Short-term, proof-of-concept.
👉Bigger/longer trials including patients with higher-risk disease needed

@PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes

🔗https://t.co/nPtK3EahPQ

[W. Keith Tan @DrWKTan]

Delighted to see that my @TheLancet article was referred to as a landmark 'Provocative' paper at DDW. I guess I like to ruffle a few feathers 🤪 @DDWMeeting
#BarrettsEsophagus

[Wei Shen Tan @drtanws]

@RaviBarodUrol So sorry for your loss. My condolences

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Had the pleasure of being a discussant on this very topic at #EAU26. My take? - Stick to the plan!

The survival benefit in EV-304/303 was built on consolidation RC+PLND - not observation, not TMT.
EV+P and radical cystectomy together deliver the advantage. Skipping surgery outside a clinical trial based on cCR alone is premature. Those studies are needed - and are underway - but we have no data yet.

#AUA2026 #AACR2026

[Wei Shen Tan @drtanws]

@benristau @UPMCUrology @FCUroOnc @NewEngland_AUA @AmerUrological @UConnUrology @uconnhealth @waterburyhosp Congratulations !

[Lee Zhao @lee_c_zhao]

Surgery is a "wicked" environment: feedback is delayed, noisy, and often biased. My essay on why experience doesn't always equal mastery, and how to learn when the feedback loops are broken.

https://t.co/mkHMtpskBV

#MedTwitter #Surgery #MedEd

[Wei Shen Tan @drtanws]

So exciting that this is now in the NCCN guidelines!

No doubt that this will better stratify IR NMIBC patients for clinical trials.

Grateful to @UroDocAsh and the @IBCG_BladderCA team for the opportunity to lead this work

https://t.co/X1QvHxC9HV

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC.

A milestone reflecting more than a decade of collaborative work by colleagues worldwide

https://t.co/VWFvAqRq4y

@UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

[Prof Veeru Kasi @veerukasi]

🚨 Gamechanger #PRIMARY2 RCT #EAU26, presented and in press @TheLancetOncol. PSMA-PET CT in men with equivocal or -ve MRI but red flags results reduces biopsy by 49% and has non-inferior csPCa detection to template biopsy in all. Proud to be part of this🚨

[Wei Shen Tan @drtanws]

Agree. BCG remains effective with minimal tox. Adding IO increases efficacy marginally with significantly increasing tox.

​Unless we see a significant reduction in MIBC progression, justifying IO for BCG-naive (or unresponsive) patients is difficult

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Our @JCO_ASCO commentary is out today:
“BCG and Beyond: Is Systemic Immunotherapy for BCG-Naïve NMIBC Progress or Overreach?”

Systemic IO has now entered the BCG-naïve high-risk NMIBC space. The signal is real. The interpretation must be disciplined.

Thread below. 🧵
#BladderCancer #GU26 #EAU26 @AndreaNecchi @BrigidaMaiorano @shilpaonc @UrogerliMD @pjhensley11 @spsutkaMD @AmirHorowitz @IBCG_BladderCA @JCO_ASCO #OncSurgery

[Yale Urology @Yale_Urology]

We are proud to share that our @drtanws has been awarded England's Royal College of Surgeons' 2026 Hunterian Professorship for his work on non-muscle invasive #bladdercancer

The award is given to those who have made an outstanding contribution to surgical research and practice.

[Wei Shen Tan @drtanws]

@vishhanchanale @UroDocAsh Many thanks !

[Wei Shen Tan @drtanws]

I’m truly honoured to receive the 2026 Hunterian Professorship from the Royal College of Surgeons of England for my work on non-muscle invasive bladder cancer.

I owe a debt of gratitude to my mentors John Kelly &amp; @UroDocAsh whose wisdom and encouragement have shaped my journey.

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Huge congratulations to @drtanws on being awarded the prestigious Hunterian Professorship by Royal College of Surgeons of England.
A well-deserved recognition of his outstanding work in defining NMIBC risk stratification in bladder cancer.
Proud to see you continue to excel and lead on the global stage!

@Yale_Urology @UCLDivofSurgery @MDAndersonNews #OncSurgery @RCSnews @SUO_YUO @UroToday

[Wei Shen Tan @drtanws]

@veerukasi @UroDocAsh Thanks Veeru. Hope you see you at EAU

[Wei Shen Tan @drtanws]

@urojdr @m_e_nielsen @UroDocAsh Many thanks !

[Wei Shen Tan @drtanws]

@RobertoContieri @UroDocAsh Thanks Roberto!

[Wei Shen Tan @drtanws]

@dougpendse @UroDocAsh Thanks!

[Wei Shen Tan @drtanws]

@acesridhar @UroDocAsh Thanks so much Ashwin! Grateful for your training in RALP and RARC.

Catch up in London during EAU!